Dario Amodei isn’t identified for being probably the most lively on X however yesterday on August 16, his two-part reply to investor Gavin Baker, CIO of Atreides Administration introduced over 14 million views as of this writing and even obtained Elon Musk to react to the thread. The second a part of the reply highlighted the prediction he’s greatest identified for in that AI will make it doable to treatment most human illnesses in round 5 to 10 years. He acknowledged how that reads by saying that the considered it doubtless sounds loopy to atypical folks and to biologists as properly.
2/2 Second, on the messaging round AI. I don’t agree that my messaging has been disproportionately damaging. In reality it has been about equally balanced between dangers and advantages: I’ve written one main essay about every, and even in interviews the place I talk about the dangers, I…
— Dario Amodei (@DarioAmodei) August 15, 2026
Why Amodei Was Replying At All
Baker had spent a part of an An-In podcast phase on Anthropic, stating that he had been advised Amodei privately introduced up the likelihood that his firm may very well be the one personal firm left on this planet, with governments working the whole lot else. Baker adopted it up on X with a broader grievance. He argued that Amodei has misplaced the regulation argument and that he needs to be a extra optimistic advocate for the business he leads.
Amodei disagreed on the framing. His two main essays cut up evenly between danger and profit, he argued and that clips taken from interviews get much more traction on social media after they sound bleak. Machines of Loving Grace, the 15,000-word essay he printed again in October 2024, was the profit half. A lot of the essay argues that AI has the potential to compress 50 to 100 years of organic progress into 5 to 10.
The Admission Connected to the Forecast
The extra helpful a part of the publish was not the prediction. It was what Amodei conceded round it.
He known as the sharpest criticism of AI corporations, his personal included, the truth that they haven’t delivered on what they promised the world. He put that squarely on the business fairly than on its critics. He additionally rejected the concept of fixing public sentiment with a advertising and marketing push, saying that promising to treatment most cancers now reads as cliché and principally comes throughout as misleading. Truly curing it’s the solely factor that works.
Then got here the timeline no person requested for. Anthropic is accelerating its work in biology and drugs, and Amodei mentioned he expects main leads to the approaching years with “some early glimmers within the coming months.”
Anthropic Has Been Shopping for Into the Thesis for Months
The declare isn’t floating free. Anthropic launched Claude for Life Sciences in October final yr, introduced analysis partnerships with the Allen Institute and the Howard Hughes Medical Institute on February 2, and reportedly acquired stealth biotech startup Coefficient Bio in a $400 million inventory deal. Coefficient’s two founders got here out of computational drug discovery at Genentech’s Prescient Design, and the roughly ten-person crew is becoming a member of Anthropic’s well being and life sciences group.
A Decade-Lengthy Name Now Has a Close to-Time period Checkpoint
Ten-year predictions are low cost as a result of no person collects on them. Amodei simply hooked up a shorter one to his.
Glimmers in months is a declare that may be checked, and shortly. He mentioned that when Anthropic accomplishes one thing actual the world will hear about it as loudly as doable, and that till then he doesn’t wish to make empty guarantees. That may be a firmer dedication than most AI executives put in writing, and the timing isn’t incidental. Anthropic filed confidentially with the SEC in June, and its backers are already modelling a $2 trillion valuation for an October itemizing. The early glimmers would land proper across the similar window.
